Fulcrum is no longer a drug-development story—it is a deeply discounted, cash-rich biotech shell whose upside depends on whether management converts a pristine balance sheet into a high-quality reverse merger.
Overview
Fulcrum Therapeutics’ clinical-stage biotech thesis has collapsed after consecutive failures in FSHD and sickle cell disease, leaving no active drug-development engine or recurring revenue. The company has cut 85% of its workforce and launched a strategic review. Its investment profile is now asset-backed: a clean Nasdaq listing, substantial cash and marketable securities, minimal liabilities, and large tax-loss assets make it a potentially attractive reverse-merger vehicle for private biotechs seeking capital and public-market access.